Amarin (AMRN) investors received a nice gift going into the weekend, after shares of the biopharma increased by almost 12% on Friday. The boost came on the heels of Thursday’s FDA AdCom vote in favor of extending the label on the company’s flagship drug, Vascepa, to include patients at risk of a heart attack and other major adverse cardiovascular events. The FDA is set to make a final decision on December 28, 2019.Vascepa is an FDA approved fish oil capsule used alongside a healthy diet to help lower fats (triglycerides) in the blood. The talk now turns to what level …read more
Source:: Yahoo Finance
